OMADA HEALTH INC (OMDA)
Health Care · Digital Health / Virtual Care · NASDAQ
Omada Health is a digital-first chronic care provider using virtual coaching and data-driven insights to manage cardiometabolic and musculoskeletal health.
What OMADA HEALTH INC does
Omada Health provides a virtual care platform that combines human-led clinical support with digital health technology to manage chronic conditions. The company offers evidence-based programs for diabetes prevention, hypertension, high cholesterol, musculoskeletal conditions, and weight health, including support for patients taking GLP-1 agonists. Their services are sold to employers, health plans, pharmacy benefit managers (PBMs), health systems, and government entities.
Themes: digital health, chronic disease management, GLP-1 / weight loss, telehealth, value-based care
Fundamentals
- Price$20.82 as of 2026-10-08 close
- Market cap$1.3B as of 2026-08-04 (share count; price 2026-10-08)
- 1-year return-13.2% 2025-10-08 close $23.98 → 2026-10-08 close $20.82
- P/En/a negative earnings
- Net margin-4.9% FY2025, SEC XBRL
- Gross margin+65.7% FY2025, SEC XBRL
- ROE-5.6% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-02
- Revenue growth (YoY)+42.0% as of 2026-09-02
- Revenue CAGR (3y)+45.6% SEC XBRL
- Beta1.09 as of 2026-09-02
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How OMDA compares in its sector
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-02
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-02
- gross marginmiddle range 189 covered Health Care peers, as of 2026-09-02
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-02
- 3-year revenue CAGRtop 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How OMADA HEALTH INC looks technically
OMADA HEALTH INC (OMDA) is trading 20.5% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 63 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 12, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 49, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 6 trading days ago (its momentum flipped positive). It made a new 20-day low about 8 trading days ago. It is 22.6% below its highest point of the past year. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 2% of the past ~6 months), which often precedes a bigger move.
Trend
8
| Distance from the 200-day | it is trading 20.5% above its 200-day average, the long-term trend line — a longer-term uptrend | +20.5% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $21.80 | $21.80 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $17.28 | $17.28 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 9 calendar days ago — the swings before that are what the structure reading is measured on | 9 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 18.68. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 63 trading days ago — a "golden cross", a bullish long-term signal | 63 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 12, below the 25 that marks a real trend) | 11.7 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 49, neither overbought (above 70) nor oversold (below 30) | 49.1 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($18.68 to $21.52) — its "stochastic" reading is 75 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 75.4 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 6 trading days ago (its momentum flipped positive) | 6 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $26.91 | $26.91 |
|---|---|---|
| From the 52-week high | it is 22.6% below its 52-week high (its highest price of the past year) | -22.6% |
| Above the 52-week low | it is 102.5% above its 52-week low (its lowest price of the past year) | +102.5% |
| Below the 52-week high | it is 22.6% below its highest point of the past year | 22.6% |
| Since a 20-day breakout | it made a new 20-day low about 8 trading days ago | 8 sessions |
| Since a 55-day breakout | it made a new 55-day high about 43 trading days ago | 43 sessions |
| All-time high | its highest closing price on record is $28.40 (set on 2025-06-06) | $28.40 |
| Given back of the 52-week move | over the past year its closes ranged ($10.94 to $26.78), and it has recovered close to two thirds of its fall from last year’s high — 62% of it. Chart-watchers call 61.8%-65% given back the "golden pocket", and this is inside it — for this company that is $20.73 to $21.24. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 62.4% |
| From the all-time high | it is 26.7% below its all-time high | -26.7% |
| Nearest price level | it is trading 1.6% below a resistance level at $21.16 — a price it turned at twice since 2025-08-08, most recently on 2025-09-11. Since 2025-06-06 it has 5 such levels below the current price and 4 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +1.6% |
| All-time low | its lowest closing price on record is $10.28 (set on 2026-02-11) | $10.28 |
| Above the all-time low | it is 102.5% above its all-time low | +102.5% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 2% of the past ~6 months), which often precedes a bigger move | 2nd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.9796 between its high and its low — about 4.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.9796 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $19.12 and $21.44 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $19.12 – $20.28 – $21.44 |
| Typical daily range (% of price) | its price moves about 4.7% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.7% |
| Stretch from the 200-day average | it is trading 3.6 daily ranges above its 200-day average price (20.5% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.6 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.68× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
2
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|---|---|
| Since a hammer | 7 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 7 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-08 0.2% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.2% |
|---|---|---|
| Gap filled | a 6.0% gap up opened on 2026-08-07 has been "filled" 19 sessions ago — price traded back through the level the gap left behind, and it took 24 sessions to close | 19 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 7.2 percentage points (the stock lost 6.1% while the market gained 1.0%) | -7.2% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 13.2 percentage points (the stock lost 9.4% while the market gained 3.8%) | -13.2% |
| vs market, 6 months | over the past 6 months this stock beat the market by 48.0 percentage points (the stock gained 65.5% while the market gained 17.5%) | +48.0% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 28.2 percentage points (the stock lost 13.2% while the market gained 15.0%) | -28.2% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, MACD momentum is positive, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 1.8% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 8.4% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -1.8% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 18% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $17.63 — a volume-weighted average of daily closes over 183 sessions, not a true tick-by-tick VWAP. | +18.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is 5% below the average price paid since it last reported on 2026-08-06 (its 8-K), so the typical buyer over that stretch is under water. That average is $21.94 — a volume-weighted average of daily closes over 45 sessions, not a true tick-by-tick VWAP. | -5.1% |
Descending triangle, either side — broke out · entry $20.65 · 45 sessions in
Price levels it has turned at before
OMDA last closed at $20.82 on 2026-10-08. Since 2025-06-06 it has turned at 5 prices below its last close and 4 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $21.16 | Resistance | 1.6% above the last close | turned there twice · 2025-08-08 to 2025-09-11 |
| $21.51 | Resistance | 3.3% above the last close | turned there twice · 2025-10-01 to 2026-09-22 |
| $19.26 | Support | 7.5% below the last close | turned there four times · 2025-07-01 to 2026-09-11 |
| $18.62 | Support | 10.6% below the last close | turned there twice · 2026-06-09 to 2026-09-29 |
| $24.38 | Resistance | 17.1% above the last close | turned there three times · 2025-09-08 to 2026-07-16 |
| $16.59 | Support | 20.3% below the last close | turned there twice · 2025-08-01 to 2025-12-29 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $18.68.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This reading has stood for 3 trading days, since 2026-10-06.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Pulled back from the 12-month high · in a Bollinger Band volatility squeeze · trendless / choppy (low ADX) · beating the market · Printed a doji candle | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · bollinger bands
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$28.42 range $22.00 – $35.00; median $28.00
Analyst estimates, as of 2026-10-04. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for OMDA
- Consensus EPS estimate$0.1026 next reporting period, as of 2026-10-04
- Estimate change, 30 days$0.00 (0.0%) from $0.1026, on 2026-08-30, 35-day window
- Readings revised upward0% of 7 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["High concentration of revenue in a limited number of customers and channel partners","Reliance on channel partners for access to end-customers, which can limit direct relationships","Unprofitable business model with ongoing investments required for growth and scaling"]
What changed in the latest 10-Q
AI-assisted comparison of OMDA's 10-Q filed 2026-05-08 against the prior one filed 2025-11-07.
Management's Discussion & Analysis (MD&A)
- Added:
- As of March 31, 2026, we had over 1,025,000 total members enrolled in one or more programs, surpassing one million total members for the first time (newer filing, 2026-05-08)
- Reference to 'high cholesterol' added to list of cardiometabolic programs offered (newer filing, 2026-05-08)
- Description of prescribing capability incorporating third-party licensed obesity care providers for anti-obesity medications (AOMs) (newer filing, 2026-05-08)
- Reference to 'Cautionary Note Regarding Forward-Looking Statements' in risk disclosure (newer filing, 2026-05-08)
- Description of Care Teams composition including licensed physical therapists depending on program (newer filing, 2026-05-08)
- Reference to 'Between-Visit Care model' and Care Team Platform capabilities (newer filing, 2026-05-08)
- Statement that Omada has 'served over two million members since launch' (newer filing, 2026-05-08)
- Expanded description of integrated technology platform supporting entire lifecycle from benefit eligibility through billing infrastructure (newer filing, 2026-05-08)
- Reference to Medicare Advantage as a new channel with significant growth potential (newer filing, 2026-05-08)
- Removed:
- Description of delivering 'virtual care between doctor's visits' (older filing, 2025-11-07)
- Reference to 'Special Note Regarding Forward-Looking Statements' in risk disclosure (older filing, 2025-11-07)
- Statement that as of September 30, 2025, we had over 831,000 total members (older filing, 2025-11-07)
- Detailed explanation of member engagement metrics (interaction definitions such as logging in, sending messages, recording metrics) (older filing, 2025-11-07)
- Discussion of 'Our History' section with detailed program launch timeline and background (older filing, 2025-11-07)
- Detailed program descriptions for Prevention & Weight Health, Diabetes, and Hypertension programs (older filing, 2025-11-07)
- Reference to U.S. Preventive Services Task Force and CDC guidelines for Prevention & Weight Health program (older filing, 2025-11-07)
- Description of members being paired with dedicated health coaches and connected devices (older filing, 2025-11-07)
- Reference to Certified Diabetes Care and Education Specialists roles (older filing, 2025-11-07)
- Reworded:
- Changed from 'deliver virtual care between doctor's visits, providing an engaging, personalized, and integrated experience' to broader overview of mission and programs without this specific framing (2026-05-08 vs 2025-11-07)
- Changed from 'We work to develop trust with each member and use technology to help us personalize their experience' to 'Omada Care Teams are supported by our proprietary Care Team Platform' as primary technology narrative (2026-05-08 vs 2025-11-07)
- Changed from detailed explanation of customer types to broader statement about 'substantial opportunity to further grow our base of customers and channel partners' (2026-05-08 vs 2025-11-07)
- Shifted from program-specific details to higher-level 'Key Factors Affecting Our Performance' framework (2026-05-08 vs 2025-11-07)
- Notes:
- The older filing text provided appears truncated at the end (cuts off mid-sentence in Omada for Hypertension section), limiting full comparison of later MD&A content
- The newer filing excerpt also appears to end mid-sentence in the 'Investments in Growth' section, limiting complete comparison
- Comparison is limited to the portions of MD&A provided; full sections may contain additional changes not visible in truncated excerpts
Risk Factors
- Added:
- Added opening paragraph stating 'These disclosures reflect the Company's beliefs and opinions as to factors that could materially and adversely affect the Company and its securities in the future. References to past events are provided by way of example only and are not intended to be a complete listing or a representation as to whether or not such factors have occurred in the past or their likelihood of occurring in the future.' (filed 2026-05-08)
- Added risk factor bullet point: 'Our programs may result in member harm or injury.' (filed 2026-05-08)
- Removed:
- Removed text at end: 'curtailment of our operations, any of which could materially and adversely affect our business, financial condition, results of operations, and prospects.' (filed 2025-11-07)
- Removed risk factor bullet point: 'Legislative or regulatory healthcare reforms or reductions in government spending may make it more difficult and costly to produce, market, and distribute our programs or to do so profitably.' (filed 2025-11-07)
- Removed text: 'We have identified material weaknesses in our internal control over financial reporting. If our remedia' (filed 2025-11-07)
- Reworded:
- Changed 'we may not achieve or maintain profitability' to 'we may not be able to consistently achieve or maintain profitability' in the net losses risk factor (filed 2026-05-08 vs 2025-11-07)
- Notes:
- The newer filing text is truncated at the end and does not include the complete final risk factor or any risk factors that may appear after the section shown
- The older filing text is also truncated and does not show complete content after the material weaknesses bullet point
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 28 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 30 days · read to 2026-10-040 buys · 8 sells ($920958) — 3 selling insiders
- Last 90 days · read to 2026-10-040 buys · 28 sells ($4M) — 4 selling insiders
- Last 180 days · read to 2026-10-040 buys · 67 sells ($10M) — 4 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-10-01. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about OMDA's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding OMDA as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 8,225,526
- Reported value $180,550,296
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about OMDA's institutional holders → See what each manager we track holds →
Short interest (FINRA)
OMDA had 7,470,777 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
OMDA had 12.2% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 5.93 days to cover at the same settlement.
- Reported short interest (shares) 7,470,777
- Short interest (% of shares outstanding) 12.2%
- Prior settlement (shares) 5,742,536
- Reported change 30.1%
- Days to cover (reported) 5.93
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Teladoc Health (TDOC)
- Livongo (Teladoc)
- Hinge Health
- Virta Health
- WeightWatchers (WW)
- Noom
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare OMDA vs…
OMADA HEALTH INC is found in…
Frequently asked questions
What does OMADA HEALTH INC (OMDA) do?
Omada Health provides a virtual care platform that combines human-led clinical support with digital health technology to manage chronic conditions. The company offers evidence-based programs for diabetes prevention, hypertension, high cholesterol, musculoskeletal conditions, and weight health, including support for patients taking GLP-1 agonists. Their services are sold to employers, health plans, pharmacy benefit managers (PBMs), health systems, and government entities.
What sector is OMADA HEALTH INC (OMDA) in?
OMADA HEALTH INC (OMDA) is classified in the Health Care sector. Its industry is Digital Health / Virtual Care. It trades on NASDAQ.
Who are OMADA HEALTH INC's (OMDA) competitors?
Notable peers of OMADA HEALTH INC (OMDA) include Teladoc Health, Livongo (Teladoc), Hinge Health, Virta Health and WeightWatchers. This peer set is informational only — not financial advice.
Is OMADA HEALTH INC (OMDA) overbought or oversold right now?
OMADA HEALTH INC (OMDA) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 49, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on OMDA come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.